A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
about
Induction of p57(KIP2) expression by p73beta.Comparative analysis of cancer genes in the human and chimpanzee genomes.The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiationIn B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosisOncogenic Intra-p53 Family Member Interactions in Human CancersMutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysMutant p53: Multiple Mechanisms Define Biologic Activity in CancerPathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.The genetics of the p53 pathway, apoptosis and cancer therapy.p73 is over-expressed in vulval cancer principally as the Delta 2 isoformp53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in TaiwanGene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancerp73 as a pharmaceutical target for cancer therapyMutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.Association between TP53 gene Arg72Pro polymorphism and Wilms' tumor risk in a Chinese population.Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.Meta-analysis reveals a lack of association between UGT2B17 deletion polymorphism and tumor susceptibility.TP53 mutations in human cancers: origins, consequences, and clinical useMutant p53 gain-of-function in cancer.p63 and p73 in tumor suppression and promotion.Single-nucleotide polymorphisms in the p53 signaling pathway.Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans.Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotypeA p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer.Mouse models for the p53 R72P polymorphism mimic human phenotypesEvaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina.Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function.The role of mutant p53 in human cancer.Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.From p63 to p53 across p73.Impact of codon 72 Arg > Pro single nucleotide polymorphism in TP53 gene in the risk of kangri cancer: a case control study in Kashmir.Analysis of Tp53 codon 72 polymorphisms, Tp53 mutations, and HPV infection in cutaneous squamous cell carcinomas.Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoterThe role of tetramerization in p53 function.p73, the "assistant" guardian of the genome?Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese populationDisruption of oncogene/tumor suppressor networks during human carcinogenesis.Role of p73 in malignancy: tumor suppressor or oncogene?Assessing TP53 status in human tumours to evaluate clinical outcome.
P2860
Q24531472-D6841938-9345-4759-ABEF-887B53A78F69Q24541311-65DA9073-909F-49DB-ABCF-4E199FA3BDD1Q24746257-77B30D18-7E98-4F22-A568-B99ABA8E8604Q24813088-2BACB635-08EB-400B-A579-3C56B829B022Q26749382-8ECCD4A6-CBF2-4AAD-A781-64FA6179F10BQ26767396-F63DA58F-4370-40B1-A5A4-00D29CE95446Q26776020-41A439D3-FCED-4C1A-8941-383A903C8834Q27863385-F0FD07F8-3A8C-441D-A2A9-7E20ADB6C5A4Q27863460-6DFC479A-B780-4185-9AA9-E169365C8DD0Q28364918-EC86972C-D112-4209-AB8F-1FFD77B99D6AQ28384167-8F1834B6-55F5-4700-941A-861425F039D1Q28392548-1D598203-E025-4C4C-8366-5400311BC3CAQ28611414-1E433110-CE5D-4CBC-9705-9BBAC9B9EF4AQ30354662-B509A026-7203-4EA5-A23C-61740BCE3E51Q30840039-66B38622-FB47-40BE-B886-63B16415D03CQ30939321-B6C2E581-00F8-4395-9E61-EE261A460BEAQ33358710-F73185E2-61BE-4C7E-A577-66510AC94D01Q33573400-D1876487-DCA1-4793-B287-37DE0E7D304EQ33685392-3A82ECF1-FEF3-4ECD-9720-17FB95A6AD6AQ33687048-1F55058B-D1D5-4517-A3D7-1694B78A72C8Q33791424-006B24BC-CFE1-4589-AF22-EB535F6332E0Q33800384-E1A2E067-6D7F-4BE8-8005-DCF73446AD87Q33809241-D6958D5E-711A-432A-B745-7FF94C4B3CB6Q33829340-93FC3DF8-EA5A-4329-AE90-B03B40906E3BQ33909710-B2A09C51-47AD-49A5-ACEC-7047976FAEB0Q34001196-A7E4EED2-CAE7-42AD-9874-4E43D7C38D01Q34012715-53D708CF-982C-4B28-90C0-2599ED4A19F8Q34114100-22F7B976-AEFE-402F-87DB-3F95F33D643DQ34153014-B0D7B05F-098B-4ACE-881E-7B4AD72B01DEQ34156507-53EE1AF2-DBC7-44C8-8363-C13D8A5D030FQ34164614-9617125E-5789-4E14-BE74-C83CE021E619Q34247581-31987B50-42E1-4330-9B7F-924535CA19AEQ34251029-B7732E35-0990-41B1-ACAF-7816421424B8Q34277205-F4458DD4-3E33-43A4-9397-067883A6C164Q34290217-FE1ABF61-6DE2-400B-99AA-5C88E060CE9EQ34307362-CD9B5BFA-82D8-4767-B0F6-CD0EAC64BCA1Q34382727-BCD03A35-CA64-4923-92C0-7045A48BA228Q34537149-0EDF0830-7408-4D45-B05A-3B0C2607FA51Q34541091-3709A1FC-9BAA-4EBD-A4BB-1E3EC2F82AD7Q34570100-D4F3398F-C22A-4FB5-B3CC-BAE2B179575D
P2860
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
description
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
articolo scientifico
@it
artículu científicu espublizáu en 2000
@ast
im Mai 2000 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2000/05/01)
@sk
vědecký článek publikovaný v roce 2000
@cs
wetenschappelijk artikel (gepubliceerd op 2000/05/01)
@nl
наукова стаття, опублікована в травні 2000
@uk
name
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@ast
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@en
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@nl
type
label
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@ast
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@en
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@nl
prefLabel
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@ast
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@en
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@nl
P2093
P3181
P356
P1433
P1476
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
@en
P2093
B. Gusterson
C. A. Harwood
C. A. Jost
I. G. Yulug
J. A. Tidy
J. M. McGregor
J. O'Nions
K. H. Vousden
L. A. Brooks
M. C. Marin
P2888
P3181
P356
10.1038/75586
P407
P577
2000-05-01T00:00:00Z